Death, discharge and arrhythmias among patients with COVID-19 and cardiac injury
Authors:
- Daoyuan SiDSDaoyuan Si
- Beibei DuBDBeibei Du
- Lujia NiLNLujia Ni
- Bo YangBYBo Yang
- Huan SunHSHuan Sun
- Nan JiangNJNan Jiang
- Guohui LiuGLGuohui Liu
- Stéphane MasséSMStéphane Massé
- Lina JinLJLina Jin
- Jared NanthakumarJNJared Nanthakumar
- Abhishek BhaskaranABAbhishek Bhaskaran
- Ping YangPYPing Yang
- 24 June 2020
- journal article
- research article
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 192 (28) , E791-E798
Abstract
BACKGROUND: Cardiac injury is common in severe coronavirus disease 2019 (COVID-19) and is associated with poor outcomes. We aimed to study predictors of in-hospital death, characteristics of arrhythmias and the effects of QT-prolonging therapy in patients with cardiac injury. METHODS: We conducted a retrospective cohort study involving patients with severe COVID-19 who were admitted to Tongji Hospital in Wuhan, China, between Jan. 29 and Mar. 8, 2020. Among patients who had cardiac injury, which we defined as an elevated level of cardiac troponin I (cTnI), we identified demographic and clinical characteristics associated with mortality and need for invasive ventilation. RESULTS: Among 1284 patients with severe COVID-19, 1159 had a cTnI level measured on admission to hospital, of whom 170 (14.7%) had results that showed cardiac injury. We found that mortality was markedly higher in patients with cardiac injury (71.2% v. 6.6%, p < 0.001). We determined that initial cTnI (per 10-fold increase, hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.06–1.66) and peak cTnI level during illness (per 10-fold increase, HR 1.70, 95% CI 1.38–2.10) were associated with poor survival. Peak cTnI was also associated with the need for invasive ventilation (odds ratio 3.02, 95% CI 1.92–4.98). We found arrhythmias in 44 of the 170 patients with cardiac injury (25.9%), including 6 patients with ventricular tachycardia or fibrillation, all of whom died. We determined that patients who received QT-prolonging drugs had longer QTc intervals than those who did not receive them (difference in medians, 45 ms, p = 0.01), but such treatment was not independently associated with mortality (HR 1.04, 95% CI 0.69–1.57). INTERPRETATION: We found that in patients with COVID-19 and cardiac injury, initial and peak cTnI levels were associated with poor survival, and peak cTnI was a predictor of need for invasive ventilation. Patients with COVID-19 warrant assessment for cardiac injury and monitoring, especially if therapy that can prolong repolarization is started. Trial registration: Chinese Clinical Trial Registry, No. ChiCTR2000031301.Keywords
This publication has 13 references indexed in Scilit:
- Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 PandemicJACC, 2020
- Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington StateJAMA, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi ArabiaInternational Journal of Infectious Diseases, 2014
- Hospital Outbreak of Middle East Respiratory Syndrome CoronavirusNew England Journal of Medicine, 2013
- Cardiovascular complications of severe acute respiratory syndromePostgraduate Medical Journal, 2006
- Increased ventricular repolarization heterogeneity in patients with ventricular arrhythmia vulnerability and cardiomyopathy: a human in vivo studyAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Critically Ill Patients With Severe Acute Respiratory SyndromeJAMA, 2003
- Repolarisation and refractoriness during early ischaemia in humansHeart, 2000